393 related articles for article (PubMed ID: 28381462)
41. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.
Wang Y; Zhang Y; Wang P; Fu X; Lin W
Mol Cancer; 2020 Oct; 19(1):149. PubMed ID: 33054773
[TBL] [Abstract][Full Text] [Related]
42. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
43. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
44. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
[TBL] [Abstract][Full Text] [Related]
45. [RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES].
Maruo K; Takahashi A; Tabata H; Takayanagi A; Takagi Y
Nihon Hinyokika Gakkai Zasshi; 2020; 111(2):58-61. PubMed ID: 33883361
[TBL] [Abstract][Full Text] [Related]
46. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
[TBL] [Abstract][Full Text] [Related]
47. Targeted therapies for renal cell carcinoma.
Posadas EM; Limvorasak S; Figlin RA
Nat Rev Nephrol; 2017 Aug; 13(8):496-511. PubMed ID: 28691713
[TBL] [Abstract][Full Text] [Related]
48. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.
Zhang Y; Narayanan SP; Mannan R; Raskind G; Wang X; Vats P; Su F; Hosseini N; Cao X; Kumar-Sinha C; Ellison SJ; Giordano TJ; Morgan TM; Pitchiaya S; Alva A; Mehra R; Cieslik M; Dhanasekaran SM; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099557
[TBL] [Abstract][Full Text] [Related]
49. Role of targeted therapy in combination with surgery in renal cell carcinoma.
Bex A; Powles T; Karam JA
Int J Urol; 2016 Jan; 23(1):5-12. PubMed ID: 26238981
[TBL] [Abstract][Full Text] [Related]
50. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.
Lebacle C; Pooli A; Bessede T; Irani J; Pantuck AJ; Drakaki A
World J Urol; 2019 Jan; 37(1):115-123. PubMed ID: 29858701
[TBL] [Abstract][Full Text] [Related]
51. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
52. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
53. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
54. Chromophobe Renal Cell Carcinoma With Retrograde Venous Invasion and Gain of Chromosome 21: Potential Harbingers of Aggressive Clinical Behavior.
Jamal M; Taneja K; Arora S; Barod R; Rogers CG; Sanchez J; Gupta NS; Williamson SR
Int J Surg Pathol; 2018 Sep; 26(6):536-541. PubMed ID: 29560759
[TBL] [Abstract][Full Text] [Related]
55. Sarcomatoid renal cell carcinoma: Biology and treatment advances.
Mouallem NE; Smith SC; Paul AK
Urol Oncol; 2018 Jun; 36(6):265-271. PubMed ID: 29306556
[TBL] [Abstract][Full Text] [Related]
56. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Patel HD; Puligandla M; Shuch BM; Leibovich BC; Kapoor A; Master VA; Drake CG; Heng DY; Lara PN; Choueiri TK; Maskens D; Singer EA; Eggener SE; Svatek RS; Stadler WM; Cole S; Signoretti S; Gupta RT; Michaelson MD; McDermott DF; Cella D; Wagner LI; Haas NB; Carducci MA; Harshman LC; Allaf ME
Future Oncol; 2019 May; 15(15):1683-1695. PubMed ID: 30968729
[TBL] [Abstract][Full Text] [Related]
57. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
58. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
59. [The present state and the future perspective of immunotherapy of renal cell carcinoma].
Kawashima H
Nihon Rinsho; 2015 Jan; 73(1):167-74. PubMed ID: 25626324
[TBL] [Abstract][Full Text] [Related]
60. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
